DIA495.91-3.14 -0.63%
SPY731.58-2.25 -0.31%
QQQ694.94-0.83 -0.12%

The Top 5 Analyst Questions From Universal Health Services’s Q1 Earnings Call

Barchart·05/04/2026 01:58:16
Listen to the news

UHS Cover Image

Universal Health Services’ first-quarter results came in ahead of Wall Street’s expectations for both revenue and non-GAAP earnings, but the market responded negatively following the report. Management attributed the quarter’s performance to a combination of robust pricing trends, outpatient behavioral health expansion, and ongoing cost discipline, despite softer volumes in both acute and behavioral segments. CEO Marc D. Miller referenced the impact of a mild flu season and winter weather on acute care admissions, while highlighting the benefits of investments in efficiency and technology, including the rollout of new AI-driven administrative solutions.

Is now the time to buy UHS? Find out in our full research report (it’s free for active Edge members).

Universal Health Services (UHS) Q1 CY2026 Highlights:

  • Revenue: $4.50 billion vs analyst estimates of $4.39 billion (9.6% year-on-year growth, 2.4% beat)
  • Adjusted EPS: $5.62 vs analyst estimates of $5.46 (2.9% beat)
  • Adjusted EBITDA: $658.3 million vs analyst estimates of $628.5 million (14.6% margin, 4.7% beat)
  • Operating Margin: 11.2%, in line with the same quarter last year
  • Same-Store Sales rose 8.2% year on year (2.4% in the same quarter last year)
  • Market Capitalization: $10.19 billion

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Universal Health Services’s Q1 Earnings Call

  • A.J. Rice (UBS): Asked about core acute EBITDA growth excluding weather and supplemental payments, and for specific AI use cases delivering value. CFO Steve G. Filton clarified core growth was in the low single digits, while CEO Marc D. Miller cited denials management and revenue cycle automation as impactful AI deployments.

  • Jason Paul Cassorla (Guggenheim): Inquired about the step-up from Medicaid supplemental payments and the expected ramp to achieve annual growth targets. Filton explained Q1 results were in line with guidance and forecasted an earnings acceleration driven by new facility openings and improved behavioral outpatient volumes.

  • Ann Hynes (Mizuho): Questioned the impact of Medicaid disenrollment on bad debt and collectability trends. Filton responded that higher reserves were taken for health insurance exchange patients and that the company’s full-year estimate for subsidy expiration remained appropriate.

  • Matthew Dale Gillmor (KeyBanc): Probed into the drivers of stronger pricing in acute care and expectations for rate moderation. Filton attributed price strength to higher-acuity patient mix and anticipated a more balanced contribution from volume and rate later in the year.

  • Craig Matthew Hettenbach (Morgan Stanley): Sought updates on the outpatient behavioral strategy and rationale for the Talkspace acquisition. Miller noted that internal outpatient initiatives are progressing and that Talkspace’s platform will complement these efforts, with confidence in earnings accretion based on integration plans.

Catalysts in Upcoming Quarters

Looking ahead, the StockStory team will be monitoring (1) the pace of Talkspace integration and its impact on behavioral health volumes, (2) the stabilization of wage inflation and resulting margin trends, and (3) the ramp-up of new hospital and bed capacity in key growth markets. The evolution of supplemental payment programs and payer mix shifts will also be critical to track for any upside or downside to guidance.

Universal Health Services currently trades at $166.60, down from $179.51 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).

Our Favorite Stocks Right Now

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week - FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

Contact Us

Contact Number :+852 3852 8500
Monday 7:00 AM - Saturday 9:00 AM (HKT)
Service Email :service@webull.hk
Online Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)
Business Cooperation :marketinghk@webull.hk
Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language

English

©2026 Webull Securities Limited. All rights reserved.